Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management

Area of Science:

• Pharmacology
• Clinical Medicine
• Pain Management

Background:

• Fibromyalgia (FM) is a complex chronic pain disorder with limited treatment options.
• Current FM treatments offer inadequate relief, highlighting a significant unmet medical need.
• The FDA recently approved sublingual cyclobenzaprine (sCBP) for FM, the first new medication in over 15 years.

Purpose of the Study:

• To review the current understanding of fibromyalgia.
• To explore the pharmacological properties, clinical trials, and benefits of sCBP for FM.
• To assess the risks and future research directions for sCBP in FM management.

Main Methods:

• Literature search for studies on FM management and sCBP development.
• Selection of articles based on relevance to study objectives.
• Synthesis of evidence from selected sources to form the manuscript's perspective.

Main Results:

• sCBP significantly reduced pain intensity in FM patients in two key clinical trials (RELIEF, RESILIENT).
• sCBP demonstrated an enhanced pharmacokinetic profile compared to oral cyclobenzaprine.
• Common side effects include oral discomfort; serious risks like serotonin syndrome warrant caution.

Conclusions:

• FDA approval of sCBP represents a major advancement in FM treatment.
• sCBP offers a promising, effective, and rapid therapeutic option for managing FM pain.
• The rising prevalence of FM underscores the importance of new treatment alternatives like sCBP.